NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC

Inclusion Criteria: * Able to understand and voluntarily sign the written informed consent form (ICF). * Male or female patients aged ≥18 years. * Histologically and/or cytologically confirmed resectable stage IB to IIIA non-small cell lung cancer (NSCLC) according to AJCC 8th edition. * Treatment-naïve NSCLC (no prior systemic anticancer therapy). * No sensitizing EGFR mutations (exon 19 deletion, exon 21 L858R) and no ALK gene rearrangement. * At least one measurable target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. * Estimated life expectancy of more than 6 months. * Eastern Cooperative Oncology Group (ECOG) performance status 0-1. * Adequate bone marrow, liver, and renal function. * Female participants of childbearing potential must have a negative pregnancy test prior to initiation of study treatment. Exclusion Criteria: * Prior receipt of any systemic anticancer therapy. * Known sensitizing EGFR mutations or ALK gene rearrangements. * Active, known, or suspected autoimmune disease. * Interstitial lung disease. * Any medical condition, therapy, or laboratory abnormality that, in the opinion of the investigator, could confound the study results, interfere with the participant's ability to comply with study procedures, or is not in the best interest of the participant. * Locally advanced unresectable or metastatic NSCLC. * Major cardiovascular events, unstable arrhythmia, or unstable angina within 3 months prior to study treatment initiation. * Pregnant or breastfeeding women, or women of childbearing potential who are unwilling to use effective contraception during the study. * Any other condition judged by the investigator to make the participant unsuitable for clinical trial participation.